Z Pharmaceuticals today announced the publication of a transformative study in Neuropsychopharmacology, highlighting compelling scientific ...

Clinical Relevance in Human Populations: Polygenic risk score analysis using the UK Biobank demonstrated that individuals with a high ADHD genetic burden who were prescribed amlodipine exhibited ...

Repurposing amlodipine, a commonly used blood pressure medicine, could help manage attention-deficit/ hyperactivity disorder (ADHD) symptoms, according to an international study involving the ...

Researchers sought to determine the prognostic value of home vs office measured pulse rate in patients with hypertension.

Apart from other risk factors for hypertension such as genetics, advancing age, obesity, stress, and insulin resistance, poor ...

Restless Leg Syndrome (RLS) used to be rare, but today it is becoming quite common. In fact, it affects between 5%-10% of ...

Milestone’s NDA for CARDAMYST is currently under review at the FDA with a Prescription Drug User Fee Act (PDUFA) target date of March 27, 2025. The Company continues to advance commercial preparations ...

Researchers say amlodipine could serve as a safer option for patients without the risks that many other drugs carry In a ...

The Prescription Drug User Fee Act (PDUFA) date refers to the deadline set by the US Food and Drug Administration (FDA) for reviewing a New Drug Application (NDA) or Biologics License Application (BLA ...

Rockwell Automation, Inc. , the world's largest company dedicated to industrial automation and digital transformation, will showcase its extensive portfolio of digital tools, advanced software and ...